News

A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared to those without IBS.

The FDA has expanded the approval of abatacept (Orencia) for the treatment of active psoriatic arthritis in patients aged 2 years and older.

The introduction of an ICD-10 code specific to IgG4-Related Disease offers a promising opportunity to revolutionize patient care, enable more accurate diagnoses, and improve outcomes.

Results from a large observational retrospective cohort of ≥500 patients with PsA show relatively low drug persistence of apremilast, an oral PDE4 inhibitor.

24-week results from the UPREAL show higher efficacy of upadacitinib among males with PsA, bio-naïve patients, and those with elevated baseline C-reactive protein.

Many studies support the finding that biologic therapy reduces the presence of psoriatic arthritis—or the risk of developing arthritis in psoriatic patients—but other research suggest the opposite.

Esme Fuller-Thomson, PhD, MSW, discusses findings from her recent study about psychiatric disorders and mental health in patients with arthritis.

A cross-sectional study of survey data shows more than 50% of psoriasis and over 60% of psoriatic arthritis patients have depressive symptoms, with results drawing a link between functional impairment and the likelihood of depressive symptoms.

While Black people are consistently underrepresented, White people are consistently overrepresented in inflammatory arthritis trials for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, and juvenile idiopathic arthritis.

Results from Mendelian randomization analyses revealed PsO and PsA did not increase the risk of basal cell carcinoma, cutaneous squamous cell carcinoma, or cutaneous melanoma.

Sex, age at disease onset, and psoriatic arthritis were associated with the greatest impact on major life-changing decisions in patients with psoriasis.

The real-world evidence study examined patients with PsA taking secukinumab and ixekizumab, highlighting 80% treatment persistence after 1 year.

A 20 mg weekly oral dose of methotrexate shows potential as a low-cost treatment for reducing pain and stiffness in patients with symptomatic hand osteoarthritis, according to the results of the METHODS trial.

Bimekizumab was found to be more cost-effective than most biologics and targeted synthetic disease-modifying antirheumatic drugs in a Swedish healthcare system-based model.

Results demonstrated a low persistence rate for apremilast among patients with PsA, highlighting a notable barrier to treatment success.

Achievement of minimal disease activity and remission were observed in approximately half of patients with psoriatic arthritis receiving upadacitinib.

This endocrine case report from Brady Pregerson, MD, features a man in his 50s with bilateral ankle and foot pain/swelling. Can you determine the correct diagnosis?

While the results showed a high prevalence of suspected musculoskeletal symptoms in patients with psoriasis, only a small number were due to psoriatic arthritis.

Hematologic malignancy was not affected by the type of biologics prescribed, treatment patterns, comedications, comorbidities, or cumulative defined daily doses.

In patients initiating allopurinal, adverse events were more common in those receiving concomitant colchicine or nonsteroidal anti-inflammatory drugs compared to those without prophylaxis.

The Patient Self-Report Survey for the Assessment of Fibromyalgia illustrated its accuracy in determining pain sensitivity and psychological factors in patients with shoulder or low back pain.

Patients with psoriatic disease have a significantly higher risk of developing a variety of autoimmune diseases, as indicated by the Charlson Comorbidity Index.

Self-injection of bimekizumab was generally well tolerated among patients with psoriatic arthritis.

This decision by the FDA could offer psoriatic arthritis patients a dosing regimen each month that does not require pre-mediation or regular lab assessments.

Retention rates for golimumab treatment at the 5-year mark were consistently high when used as a first-line therapy and did not significantly differ across conditions.

The overall cardiovascular burden was significantly higher in the fibromyalgia cohort when compared with the general Italian population.

At week 52, sustained remission was observed in significantly more patients receiving sarilumab compared with placebo.

Investigators found intestinal permeability and fecal and plasma metabolomic profiles of patients with PsA in the FLORA trial cohort were associated with clinical response to FMT.

A systematic literature search reported an increase in both publications and cases of spinal gout.

Although the dietary intervention did not significantly reduce overall serum urate, it did decrease levels among those with baseline hyperuricemia.